Recent News

• 10.29.2026 - New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*
• 10.26.2026 - LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026
• 10.12.2026 - LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.18.2026 - LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026
• 08.27.2026 - LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026
• 08.21.2026 - LifeVantage Declares Quarterly Dividend
• 08.13.2026 - LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2026 Results on August 27, 2026
• 08.11.2026 - LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2026 - LifeVantage Welcomes Terrence Moorehead as Chief Executive Officer
• 05.06.2026 - LifeVantage Declares Quarterly Dividend

Recent Filings

• 10.22.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.05.2026 - 8-K Current report
• 09.18.2026 - ARS Annual Report to Security Holders
• 09.18.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 09.18.2026 - DEF 14A Other definitive proxy statements